This marks the second asset buy in as many days for Insulet. Yesterday, the company picked up automated insulin delivery patents from Bigfoot Biomedical. Both acquisitions cost the company $25 million.
Palo Alto, California-based Automated Glucose Control (ACG) focuses on developing and commercializing best-in-class automated insulin delivery (AID) technology. Insulet develops its own AID platform, with the Omnipod 5 representing the latest iteration, having received FDA clearance last year.
Acton, Massachusetts-based Insulet entered into a license agreement and partnership with ACG in 2016. This agreement centered around patents and IP ACG licensed from the Dr. Francis J. Doyle III laboratory at the University of California, Santa Barbara.
Get the full story at our sister site, Drug Delivery Business News.
